Women with limited treatment options can treat their uUTI with a penem at home1,2
ORLYNVAH is the first and only oral penem in the United States. It is for adult women with uncomplicated UTI (urinary tract infection) caused by E coli, K pneumoniae, or P mirabilis in adult women with limited or no alternative oral antibacterial options.
ORLYNVAH showed activity against1:
| In Clinical Trials |
|---|
|
Sulopenem showed in vitro activity against:
The efficacy of ORLYNVAH in treating these bacteria has not been established in adequate and well-controlled clinical trials.
| In Vitro Studies |
|---|
Gram-negative bacteria
Gram-positive bacteria
|
How ORLYNVAH works
ORLYNVAH is a novel treatment with a mechanism of action that offers a unique combination of sulopenem etzadroxil and probenecid in a single bilayer tablet. The addition of probenecid increases the bioavailability of sulopenem in the body.1
Sulopenem etzadroxil1
Is converted after ingestion to sulopenem, the active drug
Sulopenem kills bacteria by attaching to penicillin-binding proteins, stopping the bacteria from building their cell walls
Probenecid1
Helps sulopenem to remain in blood plasma for longer, improving the bioavailability of sulopenem
Who is right for ORLYNVAH?
Consider ORLYNVAH for patients like these
Demonstrated clinical response
Proven efficacy against ciprofloxacin-resistant pathogens1,3